Clinical Trial

Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients with CD20-positive hematological malignancies.
Trial Details
NCT Number NCT07110194
Lead Sponsor Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions CD20-positive Hematological Malignancies
Enrollment 75 participants
Start Date 2025-09
Primary Completion 2026-03 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-07